Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00437151 |
Recruitment Status :
Completed
First Posted : February 19, 2007
Last Update Posted : July 29, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acne | Other: More frequent than normal office visits Other: Electronic reminders (voice, e-mail, text messages) Other: Parenteral involvement / intervention reminders Other: No intervention or reminders | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 61 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris. |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | June 2007 |
Actual Study Completion Date : | June 2007 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
More frequent than normal office visits
|
Other: More frequent than normal office visits
Mode of patient reminder |
Active Comparator: 2
Electronic reminders (voice, e-mail, text messages)
|
Other: Electronic reminders (voice, e-mail, text messages)
Mode of patient reminder |
Active Comparator: 3
Parental involvement / intervention reminders
|
Other: Parenteral involvement / intervention reminders
Mode of patient reminder |
Active Comparator: 4
No intervention or reminders
|
Other: No intervention or reminders
Mode of patient reminder |
- Efficacy - Percent adherence calculated from MEMS Caps readings [ Time Frame: 12 weeks ]
- Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject's Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire [ Time Frame: 12 weeks ]
- Safety - tolerability and adverse event reporting [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adolescent subjects with a diagnosis of moderate to severe Acne vulgaris
Exclusion Criteria:
- Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring more than topical treatment (e.g. oral isotretinoin)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00437151
United States, North Carolina | |
Wake Forest School of Medicine | |
Winston-Salem, North Carolina, United States, 27157 |
Study Director: | Ronald W Gottschalk, MD | Galderma Laboratories, LP |
Responsible Party: | Ronald W. Gottschalk, MD / Medical Director, Galderma Laboratories, L.P. |
ClinicalTrials.gov Identifier: | NCT00437151 |
Other Study ID Numbers: |
US10022 |
First Posted: | February 19, 2007 Key Record Dates |
Last Update Posted: | July 29, 2022 |
Last Verified: | March 2008 |
Acne Vulgaris Acneiform Eruptions Skin Diseases Sebaceous Gland Diseases |